Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin

Cancer Research

Volumn 67, Issue 7, 2007, Pages 3345-3355

  Cui, Hongyan ^a   Darmanin, Stephanie ^a   Natsuisaka, Mitsuteru ^a   Kondo, Takeshi ^a   Asaka, Masahiro ^a   Shindoh, Masanobu ^b   Higashino, Fumihiro ^b   Hamuro, Junji ^c,d   Okada, Futoshi ^e   Kobayashi, Masataka ^c   Nakagawa, Koji ^c   Koide, Hideyuki ^c   Kobayashi, Masanobu ^a,b,c  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c Oncorex Inc   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e YAMAGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ASPARTATE AMMONIA LIGASE; CISPLATIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PACLITAXEL; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; ASPARAGINE;

AMINO ACID SEQUENCE; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA MICROARRAY; DRUG SENSITIVITY; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOXIA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; BIOSYNTHESIS; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; ASPARAGINE; ASPARTATE-AMMONIA LIGASE; CELL LINE, TUMOR; CISPLATIN; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; PANCREATIC NEOPLASMS; PHOSPHORYLATION; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 34248136068     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2519     Document Type: Article

References (41)

1. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
2. Jiang CQ, Fan LF, Liu ZS, et al. Expression levels and significance of hypoxia inducible factor-1α and vascular endothelial growth factor in human colorectal adenocarcinoma. Chin Med J (Engl) 2004;117:1541-6.
3. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004;5:10-7.
4. Semenza GL. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 2001;7:345-50.
5. Semenza GL. Perspectives on oxygen sensing. Cell 1999;98:281-4.
6. Greijer AE, van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 2004;57:1009-14.
7. Evans SM, Hahn SM, Magarelli DP, Koch CJ. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am J Clin Oncol 2001; 24:467-72.
8. Kim JY, Ahn HJ, Ryu JH, Suk K, Park JH. BH3-only protein noxa is a mediator of hypoxic cell death induced by hypoxia-inducible factor 1α. J Exp Med 2004;199:113-24.
9. Papandreou I, Krishna C, Kaper F, Cai D, Giaccia AJ, Denko NC. Anoxia is necessary for tumor cell toxicity caused by a low-oxygen environment. Cancer Res 2005; 65:3171-8.
10. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-16.
11. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999;24:68-72.
12. Hockel M, Schlenger K, Hockel S, Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999;59:4525-8.
13. Malhotra R, Brosius FC III. Glucose uptake and glycolysis reduce hypoxia-induced apoptosis in cultured neonatal rat cardiac myocytes. J Biol Chem 1999;274: 12567-75.
14. Esumi H, Izuishi K, Kato K, et al. Hypoxia and nitric oxide treatment confer tolerance to glucose starvation in a 5′-AMP-activated protein kinase-dependent manner. J Biol Chem 2002;277:32791-8.
15. Suzuki A, Kusakai G, Shimojo Y, et al. Involvement of transforming growth factor-β1 signaling in hypoxia-induced tolerance to glucose starvation. J Biol Chem 2005;280:31557-63.
16. Koito K, Namieno T, Nagakawa T, et al. Congenital arteriovenous malformation of the pancreas: its diagnostic features on images. Pancreas 2001;22:267-73.
17. Richards NG, Kilberg MS. Asparagine synthetase chemotherapy. Annu Rev Biochem 2006;75:629-54.
18. Scian MJ, Stagliano KE, Deb D, et al. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. Oncogene 2004;23: 4430-43.
19. Richards NG, Schuster SM. Mechanistic issues in asparagine synthetase catalysis. Adv Enzymol Relat Areas Mol Biol 1998;72:145-98.
20. Fafoumoux P, Brahat A, Jousse C. Amino acid regulation of gene expression. Biochem J 2000;351:1-12.
21. Barbosa-Tessmann IP, Pineda VL, Nick HS, Schuster SM, Kilberg MS. Transcriptional regulation of the human asparagine synthetase gene by carbohydrate availability. Biochem J 1999;339:151-8.
22. Luo Z, Saha AK, Xiang X, Ruderman NB. AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 2005;26:69-76.
23. Carling D. The AMP-activated protein kinase cascade - a unifying system for energy control. Trends Biochem Sci 2004;29:18-24.
24. Hardie DG. New roles for the LKB1-AMPK pathway. Curr Opin Cell Biol 2005;17:167-73.
25. Siu F, Bain PJ, LeBlanc-Chaffin R, Chen H, Kilberg MS. ATF-4 is a mediator of the nutrient-sensing response pathway that activates the human asparagine synthetase gene. J Biol Chem 2002;277:24120-7.
26. Chen C, Dudenhausen E, Chen H, Pan YX, Gjymishka A, Kilberg MS. Amino-acid limitation induces transcription from the human C/EBPβ gene via an enhancer activity located downstream of the protein coding sequence. Biochem J 2005;391:649-58.
27. Barbosa-Tessmann IP, Chen C, Zhong C, Schuster SM, Nick HS, Kilberg MS. Activation of the unfolded protein response pathway induces human asparagine synthetase gene expression. J Biol Chem 1999;274:31139-44.
28. Cooney DA, King VD, Cable RG, Taylor B, Jr., Wodinsky I. L-Asparagine synthetase in serum as a marker for neoplasia. Cancer Res 1976;36:3238-45.
29. Greco A, Gong SS, Ittmann M, Basilico C. Organization and expression of the cell cycle gene, ts11, that encodes asparagine synthetase. Moll Cell Biol 1989;9: 2350-9.
30. Aslanian AM, Fletcher BS, Kilberg MS. Asparagine synthetase expression alone is sufficient to induce L-asparaginase resistance in MOLT-4 human leukaemia cells. Biochemical J 2001;357:321-8.
31. Masuda M, Toh S, Koike K, et al. The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil. Jpn J Cancer Res 2002;93:329-39.
32. Kang CD, Ahn BK, Jeong CS, et al. Down-regulation of JNK/SAPK activity is associated with the cross-resistance to P-glycoprotein-unrelated drugs in multidrug-resistant FM3A/M cells overexpressing P-glycoprotein. Exp Cell Res 2000;256:300-7.
33. Boldt S, Weidle UH, Kolch W. The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 2002;23:1831-8.
34. Ham YM, Choi JS, Chun KH, Joo SH, Lee SK. The c-Jun N-terminal kinase 1 activity is differentially regulated by specific mechanisms during apoptosis. J Biol Chem 2003;278:50330-7.
35. Nishina H, Vaz C, Billia P, et al. Defective liver formation and liver cell apoptosis in mice lacking the stress signaling kinase SEK1/MKK4. Development 1999; 126:505-16.
36. Nishina H, Radvanyi L, Raju K, Sasaki T, Kozieradzki I, Penninger JM. Impaired TCR-mediated apoptosis and Bcl-XL expression in T cells lacking the stress kinase activator SEK1/MKK4. J Immunol 1998;161:3416-20.
37. Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 2005;115:2656-64.
38. Schroder M, Kaufman BJ. ER stress and the unfolded protein response. Mutat Res 2005;569:29-63.
39. Yun H, Lee M, Kim SS, Ha J. Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma J Biol Chem 2005;280:9963-72.
40. Koong AC, Chauhan V, Romero-Ramirez L. Targeting XBP-1 as a novel anti-cancer strategy. Cancer Biol Ther 2006;5:756-9.
41. Fels DR, Koumenis C. The PERK/eIF2α/ATF-4 module of the UPR in hypoxia resistance and tumor growth. Cancer Biol Ther 2006;5:723-8.